LegoChem Biosciences Inc (141080) - Total Assets
Based on the latest financial reports, LegoChem Biosciences Inc (141080) holds total assets worth ₩652.93 Billion KRW (≈ $442.48 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check LegoChem Biosciences Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
LegoChem Biosciences Inc - Total Assets Trend (2014–2025)
This chart illustrates how LegoChem Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Explore LegoChem Biosciences Inc (141080) investment intensity to see how much of total assets are deployed in long-term investments.
LegoChem Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
LegoChem Biosciences Inc's total assets of ₩652.93 Billion consist of 74.3% current assets and 25.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 14.1% |
| Accounts Receivable | ₩11.76 Billion | 1.7% |
| Inventory | ₩110.04 Million | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩88.40 Billion | 12.6% |
| Goodwill | ₩16.08 Billion | 2.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how LegoChem Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 141080 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LegoChem Biosciences Inc's current assets represent 74.3% of total assets in 2025, a decrease from 90.7% in 2014.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, up from 4.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
LegoChem Biosciences Inc Competitors by Total Assets
Key competitors of LegoChem Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
LegoChem Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.12 | 5.32 | 5.73 |
| Quick Ratio | 10.12 | 5.32 | 5.71 |
| Cash Ratio | 0.00 | 0.26 | 1.27 |
| Working Capital | ₩432.53 Billion | ₩437.57 Billion | ₩52.45 Billion |
LegoChem Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between LegoChem Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | ₩701.81 Billion |
| Market Capitalization | $3.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values LegoChem Biosciences Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LegoChem Biosciences Inc's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LegoChem Biosciences Inc (2014–2025)
The table below shows the annual total assets of LegoChem Biosciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩701.81 Billion ≈ $475.61 Million |
-4.95% |
| 2024-12-31 | ₩738.38 Billion ≈ $500.39 Million |
+289.64% |
| 2023-12-31 | ₩189.50 Billion ≈ $128.42 Million |
-24.96% |
| 2022-12-31 | ₩252.53 Billion ≈ $171.14 Million |
-13.88% |
| 2021-12-31 | ₩293.23 Billion ≈ $198.72 Million |
+115.75% |
| 2020-12-31 | ₩135.91 Billion ≈ $92.11 Million |
-3.93% |
| 2019-12-31 | ₩141.48 Billion ≈ $95.88 Million |
+16.26% |
| 2018-12-31 | ₩121.69 Billion ≈ $82.47 Million |
+47.97% |
| 2017-12-31 | ₩82.24 Billion ≈ $55.73 Million |
-8.17% |
| 2016-12-31 | ₩89.55 Billion ≈ $60.69 Million |
+30.84% |
| 2015-12-31 | ₩68.44 Billion ≈ $46.38 Million |
+102.75% |
| 2014-12-31 | ₩33.76 Billion ≈ $22.88 Million |
-- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more